Hinova Pharmaceuticals Inc. announced that it has signed a Series B preferred shares purchase agreement of 2,188,244 preferred shares at a price of $2.28494 for the total gross proceeds of $5,000,006.24536 with Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623) on December 20, 2019. The company will issue 1.57% stakes to the investor.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
25.2 CNY | -0.47% |
|
-11.02% | -51.60% |
06-24 | Hinova Pharmaceuticals Inc.(XSSC:688302) dropped from S&P Global BMI Index | CI |
04-26 | Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-51.60% | 345M | |
+38.36% | 52.5B | |
+36.73% | 39.31B | |
-8.63% | 39.01B | |
+25.46% | 28.2B | |
-11.17% | 26.57B | |
+11.44% | 26.2B | |
+45.09% | 14.15B | |
+32.93% | 12.62B | |
-5.30% | 11.74B |
- Stock Market
- Equities
- 688302 Stock
- News Hinova Pharmaceuticals Inc.
- Hinova Pharmaceuticals Inc. announced that it expects to receive $5.000006 million in funding from Jilin Aodong Pharmaceutical Group Co., Ltd.